Muna Therapeutics vs Hoppscotch
Side-by-side comparison of AI visibility scores, market position, and capabilities
Muna Therapeutics raised $75M in 2024 targeting microglial biology in Alzheimer's disease, using iPSC-derived microglia models to identify novel drug targets that modulate brain immune function.
About
Muna Therapeutics focuses on microglial biology — the specialized immune cells of the brain — as the key to developing disease-modifying Alzheimer's therapies beyond amyloid targeting. The company uses induced pluripotent stem cell (iPSC)-derived microglia as disease models to identify and validate novel drug targets implicated by Alzheimer's genetics (TREM2, PLCG2, BIN1, APOE). This platform enables the company to study microglial dysfunction at scale and run drug screens against human-relevant cellular models.
Open-source browser-based API testing platform with 500K+ developers; $3M seed from OSS Capital competing with Postman as a lightweight, self-hostable alternative for REST and GraphQL testing.
About
Hoppscotch is an open-source API development and testing platform — providing a web-based, lightweight alternative to Postman and Insomnia for building, testing, and documenting REST, GraphQL, WebSocket, and gRPC APIs. Founded in 2019 by Liyas Thomas and Andrew Bastin in Kochi, India, Hoppscotch has grown to 500,000+ developers globally using the platform, raised $3 million in seed funding led by OSS Capital with participation from Automattic (WordPress.com parent), and offers a free open-source version alongside Hoppscotch Pro cloud with team collaboration and private workspaces.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.